AI Summary & Key Takeaways
AI InsightPSP may be a new marker for DHF.
📌 3 Key Takeaways
Özet
Objective: Recently, the soluble CD14 subtype; presepsin (PSP) has been suggested as a reliable marker for systemic inflammation, which has not been studied in decompensated heart failure (DHF) up to date. Our aim was to investigate plasma PSP levels and its diagnostic ability in patients with DHF. Methods: Fifty patients with DHF and 51 controls without HF were included in our study. Besides routine clinical and laboratory data, N-terminal prohormone of brain natriuretic peptide (NT-pro BNP) and PSP levels were measured in blood samples of all the participants. Results: PSP levels were significantly higher in patients with DHF than controls (1107.98 ± 1001.15 vs. 540.47 ± 526.9 pg / mL, p = 0.001). Cut-off value for PSP was 442 pg / mL to detect HF with 76% sensitivity, 62.7% specificity, 66.7% positive predictive value and 72.7% negative predictive value (CI: 0.975 - 1.000). The diagnostic accuracy of PSP for DHF was not superior to that of NT-pro BNP (AUC: 0.99 vs. 0.74) Conclusions: This preliminary study reveals that PSP levels are significantly elevated in patients with DHF but the diagnostic power of PSP for DHF is lower than NT-pro BNP. PSP may be a new marker for DHF.